Celularity closes $10m first tranche of $28m recapitalisation
Celularity Inc. (Nasdaq: CELU), the New Jersey-based placenta-derived cell therapy company, has completed the initial closing of a broader recapitalisation plan, generating just over $10 million in gross cash proceeds through a private placement of senior secured convertible notes and accompanying warrants.
The initial tranche forms part of a transaction that contemplates up to $25 million in new cash investment alongside the restructuring of approximately $3 million in existing debt, bringing the total package to as much as $28 million. Additional closings remain conditional on investor elections and other terms set out in the definitive agreements, and the company cautioned that there is no guarantee the full amount will be raised.
Deal structure and use of proceeds
The notes carry a 10% annual interest rate, mature 24 months from issuance and are initially convertible into Class A common stock at $1.50 per share. Each note comes with five-year warrants also priced at $1.50, providing eleven warrant shares for every twenty shares issuable upon conversion. Odeon Capital Group acted as placement agent on the initial closing.
Celularity said the proceeds will support commercial execution and the expansion of manufacturing relationships, with a particular emphasis on increasing utilisation at its purpose-built Florham Park facility. The company highlighted an existing inventory of cenplacel-L, its investigational placenta-derived allogeneic cell therapy, which management estimates represents approximately $40 million in potential sales value. Deployment is expected to proceed through commercial relationships in jurisdictions where supply and use of the investigational product are locally authorised.
Philip A. Barach, whose prior investment in the company preceded this round, is to join the board of directors as part of the transaction. Robert J. Hariri, chairman and chief executive, framed the raise as a pivot from asset-building to commercial delivery. "Our lower cost structure, existing cellular product inventory and purpose-built manufacturing facility provide a powerful foundation for growth," he said.
Market context and competitive position
The recapitalisation comes after Celularity reduced its monthly cash burn by more than $1 million through personnel and spending optimisation. Management is guiding for positive monthly operating cash flow by the end of Q1 2027, a target that depends on manufacturing revenue growth and conversion of the cenplacel-L inventory before expiration or obsolescence risks materialise.
Celularity occupies an unusual position in the cell therapy landscape. Most commercial-stage allogeneic cell therapy programmes focus on oncology and are competing for reimbursement in established healthcare markets, whereas Celularity is positioning its platform across regenerative medicine and what it terms "longevity therapeutics." That framing carries both opportunity and risk: the longevity segment lacks a clear regulatory or reimbursement pathway in the United States, and revenue from investigational products in permissive offshore markets is structurally harder to sustain than domestically approved therapies.
The company's collaboration with MuseCell Innovations, which uses the Florham Park site to manufacture the Dezawa MuseCell platform, illustrates the contract-manufacturing-services model Celularity is pursuing to monetise its infrastructure while its own pipeline matures. This approach has precedent among cell therapy companies that have struggled with the capital intensity of maintaining GMP facilities at sub-commercial utilisation, though success depends heavily on the volume and credit quality of third-party manufacturing contracts secured.
Investors will be watching the company's progress on regaining full Nasdaq compliance, completing delinquent SEC filings and achieving the Q1 2027 cash-flow target as the near-term milestones that will determine whether the remaining tranches of the recapitalisation materialise.